Merck & Co. Inc. announced that data from multiple clinical studies across its portfolio of approved and investigational medicines for genitourinary cancers will be presented at the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, scheduled for February 26-28. Among the presentations will be new findings for KEYTRUDA® (pembrolizumab), WELIREG® (belzutifan), and LENVIMA® (lenvatinib), as well as results for the investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT). These studies include research in muscle invasive bladder cancer and earlier stages of renal cell carcinoma. The results have not yet been presented and will be disclosed at the upcoming symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212223128) on February 12, 2026, and is solely responsible for the information contained therein.